|
 |
Obchodní název |
|
|
Trade names are indicative and excipients composition can be different depending on the country and manufacturers
|
|
Mabthera |
äpanÏlsko, Argentina, Austrálie, Belgie, Chile, Chorvatsko, Dánsko, Egypt, Ekvádor, Finsko, Francie, Irsko, Island, Itálie, Japonsko, Kolumbie, Lucembursko, MaÔarsko, Maroko, Mexiko, NÏmecko, Nizozemsko, Norsko, nový Zéland, Peru, Polsko, Portugalsko, Rakousko, Rumunsko, Saúdská Arábie, Spojené arabské emiráty, Švédsko, Švýcarsko, Tunisko, Turecko, Velká Británie, Venezuela, ÿecko |
|
Novex |
Argentina |
|
Reditux |
Chile, Peru |
|
Rigetuxer |
Mexiko |
|
Rituxan |
Japonsko, Kanada, USA |
|
Rituximab |
nový Zéland |
|
Rixathon |
äpanÏlsko, Belgie, Francie, NÏmecko, Švýcarsko, Velká Británie |
|
Truxima |
äpanÏlsko, Belgie, Francie, Kanada, NÏmecko, USA, Velká Británie |
|
|
 |
 |
Odkazy : Rituximab |
|
|
typ |
uveřejnění |
| 2296 |
Laboratoř |
Témocilline (Negaban®) - Résumé des caractéristiques du produit
Eumedica 2017 |
| 2825 |
noviny |
Mueller C, Dietel E, Heynen S, Nalenz H, Goldbach P, Mahler H, Schmidt J, Grauschopf U, Schoenhammer K.
Physico-chemical Stability of MabThera Drug-product Solution for Subcutaneous Injection under In-use Conditions with Different Administration Materials.
Int J Pharm Compound 2015 ; 19, 3: 261-267. |
| 2881 |
plakát |
Jaccoulet E, Guirao S, Morand K, Astier A, Paul M.
Stabilité d'un anticorps monoclonal d'intérêt thérapeutique après reconstitution: le rituximab.
SFPO Congress 2009 |
| 3323 |
noviny |
Paul M, Vieillard V, Jaccoulet E, Astier A.
Long-term stability of diluted solutions of the monoclonal antibody rituximab.
Int J Pharm 2012 ; 436, 1-2: 282-290. |
| 4016 |
noviny |
Vieillard V, Paul M, Ibrahim T, Astier A.
Extended stability of the rituximab biosimilar CT-P10 in its opened vials and after dilution and storage in polyolefin bag.
Ann Pharm Fr 2017 ; 75, 6: 420-435. |
| 4040 |
noviny |
Lamanna W.C, Heller K, Schneider D, Guerrasio R, Hampl V, Fritsch C, Schiestl M.
The in-use stability of the rituximab biosimilar Rixathon®/Riximyo® upon preparation for intravenous infusion.
J Oncol Pharm Practice 2017 ;25,2: 269-278 |
| 4676 |
plakát |
Borišek R, Šmid I.
Assessing the stability of Sandoz rituximab biosimilar after exposure to out-of-fridge conditions for 21 days.
EAHP Congress Vienna 2022 |
| 4708 |
noviny |
Borišek R, Mischo A, Šmid I.
Study of the Stability of Sandoz Rituximab Biosimilar Rixathon®/Riximyo® When Subjected for up to 21 Days to Ambient Storage.
Drugs R D 2022 ; 22,3: 225–234 |
| 4740 |
Laboratoř |
MabThera 500 mg concentrate for solution for infusion. Summary of Product Characteristics Updated 07-Oct-2021
Roche Products Limited 2021 |
|
|
